INCY vs PGNY: fair value comparison
Incyte Corporation and Progyny, Inc. · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, PGNY currently sits closer to the top of our discount ranking.
| INCY | PGNY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $126.75 | $31.53 |
| 12-month range | $93.48–$125.01 | $16.86–$31.53 |
| Sector rank | #37 of 113 Healthcare | #32 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: INCY fair value analysis · PGNY fair value analysis